Maximum quantity allowed is 999
请选择数量
CAS RN: 945667-22-1 | 产品编码: A3435
Saxagliptin Hydrate
×
![]()
×
纯度/分析方法: >98.0%(T)(HPLC)
别名：
- 沙格列汀 水合物
- (1S,3S,5S)-2-[(S)-2-氨基-2-[(1r,3R,5R,7S)-3-羟基金刚烷-1-基]乙酰基]-2-氮杂双环[3.1.0]己烷-3-甲腈 水合物
- (1S,3S,5S)-2-[(S)-2-Amino-2-[(1r,3R,5R,7S)-3-hydroxyadamantan-1-yl]acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile Hydrate
产品文档：
| 产品编码 | A3435 |
纯度/分析方法 
|
>98.0%(T)(HPLC) |
| 分子式/分子量 | C__1__8H__2__5N__3O__2·H__2O = 333.44 |
| 外观与形状（20°C） | 固体 |
| 储存温度
|
冷冻 (-20°C) |
| 储存在惰性气体下 | 存放于惰性气体之中 |
| 应避免的情况 | 空气,加热 |
| 包装和容器
|
250MG-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 945667-22-1 |
| Reaxys-RN | 18655324 |
| PubChem物质ID | 468590297 |
| MDL编号 | MFCD26131254 |
技术规格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 136.0 to 140.0 °C |
| Specific rotation | +6.0 to +7.0 deg(C=0.4, Methanol) |
| Water | 5.0 to 6.0 % |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 138 °C |
| 溶解性（微溶于） | 乙醇 |
GHS
| 象形图 |
|
| 信号词 | Warning |
| 危险性说明 | H317 : May cause an allergic skin reaction. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P261 : Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray. P272 : Contaminated work clothing should not be allowed out of the workplace. P280 : Wear protective gloves. P302 + P352 : IF ON SKIN: Wash with plenty of water. P362 + P364 : Take off contaminated clothing and wash it before reuse. P333 + P313 : If skin irritation or rash occurs: Get medical advice/ attention. |
相关法规
运输信息
| HS编码* | 2933.99-000 |
应用
Saxagliptin: A Long-Acting Dipeptidyl Peptidase-4 (DPP-4) Enzyme Inhibitor
Saxagliptin (BMS-477118) is a long-acting dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor which is a new class of anti-hyperglycemic agents. Released into the small intestine in response meals, incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin tropic polypeptide (GIP) are known to be gastrointestinal hormones that promote insulin secretion and suppress glucagon secretion in a glucose concentration-dependent manner. Saxagliptin inhibits the activity of DPP-4 that degrades and inactivates GLP-1 and GIP. Through this inhibition, saxagliptin increases the blood concentration of active GLP-1, and exerts its hypoglycemic effect through increasing insulin secretion and reducing glucagon secretion. (The product is for research purpose only.)
References
- Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
- Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections
- Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus (a review)
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- Development and validation of a method for simultaneous determination of metformin and saxagliptin in a formulation by RP-HPLC
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。